Join
Live feed
·
INSIDERFilingvia Quantisnow
AN2 Therapeutics Inc. logo

Chief Development Officer Chanda Sanjay sold $9,332 worth of shares (9,251 units at $1.01), decreasing direct ownership by 11% to 75,823 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ANTX· AN2 Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANTX (AN2 Therapeutics Inc.) and more on Quantisnow.